Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 2/2010

01-04-2010 | SHORT REPORT

Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction

Authors: Simona Potenza, Guglielmo Nasti, Ottaiano Alessandro, Amelia Filippelli, Francesco Rossi, Annalisa Capuano

Published in: Investigational New Drugs | Issue 2/2010

Login to get access

Summary

A 46-year-old man with adenocarcinoma of the sigmoid colon developed a hypersensitivity reaction after the sixth cycle of combination chemotherapy with oxaliplatin infusion. Hypersensitivity to oxaliplatin occurring, after several courses of therapy, in about 10–15% of patients, especially during or immediately after the oxaliplatin infusion. In this case report we present a delayed hypersensitivity reaction, consisting in dysesthesia and laryngeal spasm developed 10 h after the sixth administration of oxaliplatin.
Literature
1.
Sarmiento R, Saponiero A, Gasparini G (2004) Therapeutic strategies to mprove the efficacy of oxaliplatin in gastrointestinal tumors. Int J Biol Markers 19:183–189PubMed
2.
3.
Gowda A, Goel R, Berdzik J et al (2004) Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology 18:1671–1675PubMed
4.
5.
6.
7.
Metadata
Title
Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction
Authors
Simona Potenza
Guglielmo Nasti
Ottaiano Alessandro
Amelia Filippelli
Francesco Rossi
Annalisa Capuano
Publication date
01-04-2010
Publisher
Springer US
Published in
Investigational New Drugs / Issue 2/2010
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-009-9250-8

Other articles of this Issue 2/2010

Investigational New Drugs 2/2010 Go to the issue

Clinical Trial Methodology

Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics

PRECLINICAL STUDIES

Comparison of the cytotoxic effect of lapachol, α-lapachone and pentacyclic 1,4-naphthoquinones on human leukemic cells

Preclinical Studies

The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug

PRECLINICAL STUDIES

F84, a quinazoline derivative, exhibits high potent antitumor activity against human gynecologic malignancies

PRECLINICAL STUDIES

N-4-iodophenyl-N′-2-chloroethylurea, a novel potential anticancer agent with colon-specific accumulation: radioiodination and comparative in vivo biodistribution profiles

PRECLINICAL STUDIES

A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits